A Phase 3 Randomized Double-blind Placebo- and Active-controlled Parallel-group Multicenter Protocol to Evaluate the Safety and Efficacy of Guselkumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease

Brief description of study

Under this protocol, there are 3 separate studies: a 48-week Phase 2 dose-ranging study (ie, GALAXI 1) and 2 identical 48-week Phase 3 confirmatory studies (ie, GALAXI 2 and GALAXI 3). All 3 studies will be conducted using a treat-through study design, ie, participants are randomized to treatment regimens at Week 0 and will remain on that treatment regimen through at least Week 48 of each study, unless otherwise indicated.


Clinical Study Identifier: s17-00614
ClinicalTrials.gov Identifier: NCT03466411
Principal Investigator: Seymour Katz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.